PEPTIQORE™

PEPTIQORE IMPURITY INTELLIGENCE

Peptide Impurity Database

Evidence-classified impurity records for priority GLP-1 class peptides. Filter by parent peptide, impurity category, evidence status and reference material availability.

10 records found

All records are classified by evidence source. Evidence status reflects the quality of available scientific support, not commercial availability. Records without sufficient evidence are not published.

PQ-IMP-000001Peer-reviewed Literature

Semaglutide Met Oxidation Impurity

Parent: Semaglutide

Oxidation product at methionine residue(s) in the semaglutide sequence. Met oxidation is a well-characterized degradation pathway for GLP-1 analogues.

Degradation-relatedOxidation-related
Custom SynthesisRequest Material
PQ-IMP-000002Peer-reviewed Literature

Semaglutide Deamidation Impurity

Parent: Semaglutide

Deamidation product at asparagine residue(s) in the semaglutide sequence. Deamidation is a relevant degradation pathway under stressed conditions.

Degradation-relatedDeamidation-related
Custom SynthesisRequest Material
PQ-IMP-000003Regulatory/Public

Semaglutide Des-Fatty Acid Impurity

Parent: Semaglutide

Semaglutide peptide backbone without the C18 fatty diacid side chain. Loss of the fatty acid modification is a relevant process and degradation impurity.

Degradation-relatedProcess-related
Custom SynthesisRequest Material
PQ-IMP-000004Peer-reviewed Literature

Semaglutide [D-His¹] Epimer

Parent: Semaglutide

Epimeric impurity at the N-terminal histidine residue. D-amino acid incorporation at position 1 is a known sequence-related impurity in GLP-1 analogues.

Sequence-relatedEpimeric
Custom SynthesisRequest Material
PQ-IMP-000005Peer-reviewed Literature

Tirzepatide Met Oxidation Impurity

Parent: Tirzepatide

Oxidation product at methionine residue(s) in the tirzepatide sequence.

Degradation-relatedOxidation-related
Custom SynthesisRequest Material
PQ-IMP-000006Regulatory/Public

Tirzepatide Des-Fatty Acid Impurity

Parent: Tirzepatide

Tirzepatide peptide backbone without the C20 fatty diacid side chain.

Degradation-relatedProcess-related
Custom SynthesisRequest Material
PQ-IMP-000007Regulatory/Public

Liraglutide Des-Fatty Acid Impurity

Liraglutide Backbone Peptide

Parent: Liraglutide

Liraglutide peptide backbone without the C16 fatty acid side chain. Loss of the palmitic acid modification via hydrolysis of the glutamic acid spacer linkage is a primary degradation and process-related impurity. This impurity has reduced albumin-binding affinity and altered pharmacokinetic profile.

Degradation-relatedProcess-related
Custom SynthesisRequest Material
PQ-IMP-000008Peer-reviewed Literature

Liraglutide Met Oxidation Impurity

Parent: Liraglutide

Oxidation product at methionine residue(s) in the liraglutide sequence. Met oxidation is a well-characterised degradation pathway for GLP-1 analogues under oxidative stress conditions. The oxidised form may be detected by LC-MS as a +16 Da mass shift.

Degradation-relatedOxidation-related
Custom SynthesisRequest Material
PQ-IMP-000009Peer-reviewed Literature

Liraglutide Deamidation Impurity

Parent: Liraglutide

Deamidation product at asparagine or glutamine residue(s) in the liraglutide sequence. Deamidation introduces a +1 Da mass shift and may affect chromatographic retention. Relevant under acidic or elevated temperature stress conditions.

Degradation-relatedDeamidation-related
Custom SynthesisRequest Material
PQ-IMP-000010Peer-reviewed Literature

Liraglutide [Arg³⁴] Sequence Variant

Liraglutide Arg34 Impurity

Parent: Liraglutide

Sequence variant with arginine at position 34. Liraglutide contains a Lys³⁴→Arg³⁴ substitution relative to native GLP-1(7-37); this impurity arises from incomplete or incorrect amino acid incorporation during synthesis. Reported in the scientific literature as a relevant process-related impurity.

Sequence-related
Custom SynthesisRequest Material